Much recent success in cancer clinical trials that blocked immune inhibitory signals, predominantly PD-L1, CTLA-4, and CD200 further underscored the importance of these inhibitory signals in reinvigorating the dysfunctional T cell responses (41). The gene discussed is CD200; the disease is cancer.